Segment & Geographic Data
Quant-Grade Normalized Data
API & CSV Delivery
Prf Technologies Ltd's Business Segments
Prf Technologies Ltd's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Reportable Segments
1
Largest Segment
Solar By Business Segments
Total Revenue
$ 0
Regions Reported
-
Annual Results
Revenue Share by Reportable Segment - FY2025
- Solar By Business Segments100%
Revenue by Reportable Segment - FY2025
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Solar By Business Segments | $ 0 | 100% |
Description of Prf Technologies Ltd
Painreform Ltd is a pharmaceutical company that specializes in the development and commercialization of innovative and effective pain management therapies. The company is headquartered in Israel and operates globally, aiming to provide solutions for various types of acute and chronic pain.
Painreform's primary focus is on developing novel drug formulations using its proprietary technology platform, which combines known analgesic drugs with its innovative delivery system. This approach allows for enhanced drug efficacy, increased duration of action, and improved patient compliance compared to conventional pain medications.
The company's core product is PRF-110, a liposomal formulation of ropivacaine (a local anesthetic) that is designed to provide effective and long-lasting pain relief for post-operative and acute pain. The liposomal encapsulation enables a controlled and sustained release of the drug, resulting in prolonged pain relief and reduced side effects. PRF-110 has the potential to revolutionize post-operative pain management and improve patients' quality of life.
Painreform's development pipeline also includes PRF-210, a novel liposomal formulation of ketorolac (a nonsteroidal anti-inflammatory drug) for the treatment of acute and chronic pain. This formulation is being investigated for its potential to provide superior pain relief, longer duration of action, and reduced systemic exposure compared to currently available pain medications.
The company is committed to conducting rigorous clinical trials to demonstrate the safety and efficacy of its products. Painreform collaborates with leading academic institutions and clinical centers to ensure the highest scientific standards and regulatory compliance.
Painreform also holds a robust intellectual property portfolio, including numerous granted and pending patents. This intellectual property protection provides a competitive advantage and ensures exclusivity for its innovative drug formulations and delivery systems.
In addition to its research and development efforts, Painreform is also focused on establishing strategic partnerships and collaborations with pharmaceutical companies and healthcare organizations to accelerate the commercialization and global distribution of its products.
Overall, Painreform Ltd is at the forefront of developing cutting-edge pain management solutions that have the potential to revolutionize the way pain is treated and managed. With its innovative drug formulations, proprietary delivery technology, and commitment to scientific excellence, the company aims to improve patients' lives and meet the growing need for effective pain management therapies.
Painreform's primary focus is on developing novel drug formulations using its proprietary technology platform, which combines known analgesic drugs with its innovative delivery system. This approach allows for enhanced drug efficacy, increased duration of action, and improved patient compliance compared to conventional pain medications.
The company's core product is PRF-110, a liposomal formulation of ropivacaine (a local anesthetic) that is designed to provide effective and long-lasting pain relief for post-operative and acute pain. The liposomal encapsulation enables a controlled and sustained release of the drug, resulting in prolonged pain relief and reduced side effects. PRF-110 has the potential to revolutionize post-operative pain management and improve patients' quality of life.
Painreform's development pipeline also includes PRF-210, a novel liposomal formulation of ketorolac (a nonsteroidal anti-inflammatory drug) for the treatment of acute and chronic pain. This formulation is being investigated for its potential to provide superior pain relief, longer duration of action, and reduced systemic exposure compared to currently available pain medications.
The company is committed to conducting rigorous clinical trials to demonstrate the safety and efficacy of its products. Painreform collaborates with leading academic institutions and clinical centers to ensure the highest scientific standards and regulatory compliance.
Painreform also holds a robust intellectual property portfolio, including numerous granted and pending patents. This intellectual property protection provides a competitive advantage and ensures exclusivity for its innovative drug formulations and delivery systems.
In addition to its research and development efforts, Painreform is also focused on establishing strategic partnerships and collaborations with pharmaceutical companies and healthcare organizations to accelerate the commercialization and global distribution of its products.
Overall, Painreform Ltd is at the forefront of developing cutting-edge pain management solutions that have the potential to revolutionize the way pain is treated and managed. With its innovative drug formulations, proprietary delivery technology, and commitment to scientific excellence, the company aims to improve patients' lives and meet the growing need for effective pain management therapies.
PainReform Ltd is a company that specializes in the development and commercialization of innovative pain management technologies. Its primary focus is on providing effective solutions for patients suffering from various pain conditions, with a strong emphasis on improving quality of life while minimizing potential side effects associated with traditional pain medications.
Segments
1. Chronic Pain Management:
- This segment targets individuals dealing with long-term pain conditions such as osteoarthritis, fibromyalgia, and neuropathic pain. PainReform Ltd is dedicated to offering solutions that can help alleviate debilitating pain, allowing patients to regain functionality and improve their overall well-being.
2. Post-operative Pain Management:
- PainReform aims to address the significant pain often experienced after surgical procedures. This segment focuses on ensuring patients have access to effective pain relief options that can help reduce the need for opioid medications, thereby alleviating concerns associated with opioid dependency and side effects.
3. Pain Management Solutions for Specific Populations:
- This segment includes tailored products for various demographic groups, such as the elderly or pediatric patients, who may have unique pain management needs. By creating specialized formulations or delivery systems, PainReform is committed to addressing these populations with sensitivity and expertise.
Products
1. PRF-110:
- One of PainReform’s flagship products, PRF-110, is formulated as a sustained-release topical treatment designed to deliver local anesthetics effectively. This product is particularly aimed at managing post-operative pain with the intention of reducing reliance on systemic pain medications.
2. Innovative Drug Delivery Systems:
- PainReform invests resources in developing advanced drug delivery technologies that enhance the efficacy of pain relief medications. These systems may include innovative formulations or devices that allow for precise and controlled release of active ingredients, thereby improving both patient outcomes and compliance.
3. Combination Therapies:
- The company explores combination therapies that utilize various pain-relief modalities to create more holistic approaches to pain management. This may include combining pharmacological agents with physical therapies or utilizing complementary approaches to maximize efficacy.
Services
1. Clinical Research and Development:
- PainReform engages in thorough clinical research to validate the safety and efficacy of its products. The company works with healthcare professionals and institutions to conduct rigorous trials that ensure their offerings meet the highest standards of quality and effectiveness.
2. Educational Initiatives:
- To support healthcare providers and patients alike, PainReform offers educational programs designed to inform about the latest advancements in pain management. These initiatives include workshops, webinars, and informational materials that aim to empower healthcare professionals with knowledge about proper pain management techniques and innovative products.
3. Patient Support Programs:
- Recognizing the challenges faced by individuals living with pain, PainReform implements patient support services that help guide patients on how to effectively manage their pain with the available products. This includes resources for understanding treatment options, potential side effects, and strategies for communicating with healthcare providers.
4. Collaborative Partnerships:
- PainReform seeks to establish partnerships with other healthcare organizations, pharmaceutical companies, and research institutions to foster innovative solutions for pain management. These collaborations can enhance development efforts and broaden the reach of their products within the medical community.
In summary, PainReform Ltd is dedicated to transforming the landscape of pain management through innovative products, comprehensive services, and a strong commitment to research. By focusing on chronic pain, post-operative care, and specialized populations, the company aims to provide effective and accessible pain relief solutions tailored to the needs of diverse patient groups.
Segments
1. Chronic Pain Management:
- This segment targets individuals dealing with long-term pain conditions such as osteoarthritis, fibromyalgia, and neuropathic pain. PainReform Ltd is dedicated to offering solutions that can help alleviate debilitating pain, allowing patients to regain functionality and improve their overall well-being.
2. Post-operative Pain Management:
- PainReform aims to address the significant pain often experienced after surgical procedures. This segment focuses on ensuring patients have access to effective pain relief options that can help reduce the need for opioid medications, thereby alleviating concerns associated with opioid dependency and side effects.
3. Pain Management Solutions for Specific Populations:
- This segment includes tailored products for various demographic groups, such as the elderly or pediatric patients, who may have unique pain management needs. By creating specialized formulations or delivery systems, PainReform is committed to addressing these populations with sensitivity and expertise.
Products
1. PRF-110:
- One of PainReform’s flagship products, PRF-110, is formulated as a sustained-release topical treatment designed to deliver local anesthetics effectively. This product is particularly aimed at managing post-operative pain with the intention of reducing reliance on systemic pain medications.
2. Innovative Drug Delivery Systems:
- PainReform invests resources in developing advanced drug delivery technologies that enhance the efficacy of pain relief medications. These systems may include innovative formulations or devices that allow for precise and controlled release of active ingredients, thereby improving both patient outcomes and compliance.
3. Combination Therapies:
- The company explores combination therapies that utilize various pain-relief modalities to create more holistic approaches to pain management. This may include combining pharmacological agents with physical therapies or utilizing complementary approaches to maximize efficacy.
Services
1. Clinical Research and Development:
- PainReform engages in thorough clinical research to validate the safety and efficacy of its products. The company works with healthcare professionals and institutions to conduct rigorous trials that ensure their offerings meet the highest standards of quality and effectiveness.
2. Educational Initiatives:
- To support healthcare providers and patients alike, PainReform offers educational programs designed to inform about the latest advancements in pain management. These initiatives include workshops, webinars, and informational materials that aim to empower healthcare professionals with knowledge about proper pain management techniques and innovative products.
3. Patient Support Programs:
- Recognizing the challenges faced by individuals living with pain, PainReform implements patient support services that help guide patients on how to effectively manage their pain with the available products. This includes resources for understanding treatment options, potential side effects, and strategies for communicating with healthcare providers.
4. Collaborative Partnerships:
- PainReform seeks to establish partnerships with other healthcare organizations, pharmaceutical companies, and research institutions to foster innovative solutions for pain management. These collaborations can enhance development efforts and broaden the reach of their products within the medical community.
In summary, PainReform Ltd is dedicated to transforming the landscape of pain management through innovative products, comprehensive services, and a strong commitment to research. By focusing on chronic pain, post-operative care, and specialized populations, the company aims to provide effective and accessible pain relief solutions tailored to the needs of diverse patient groups.